The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 655.00
Bid: 658.00
Ask: 659.00
Change: -0.50 (-0.08%)
Spread: 1.00 (0.152%)
Open: 643.00
High: 664.00
Low: 643.00
Prev. Close: 655.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

8 Oct 2015 07:00

8 October 2015 - Tate & Lyle PLC

Trading Update

Tate & Lyle issues the following trading update for the six months ended 30 September 2015 ahead of the announcement of Half Year Results on Thursday 5 November 2015.

OPERATING PERFORMANCE – CONTINUING OPERATIONS

The Group’s trading performance in the first half was in line with our expectations and guidance for the full year remains unchanged.

Speciality Food Ingredients performed encouragingly and ahead of the comparative period. As anticipated, the Speciality Food Ingredients business returned to volume growth in the second quarter. Volumes were also ahead of the comparative period in SPLENDA® Sucralose and, following the Gemacom acquisition, strongly ahead in Food Systems.

Bulk Ingredients, excluding commodities (ethanol and co-products), continued to perform steadily and slightly ahead of the comparative period supported by solid sweetener demand. Commodities, which continued to be impacted by low US ethanol margins, were significantly lower than the comparative period, and, as a result, Bulk Ingredients overall performed below the comparative period.

The annual bulk sweetener pricing round is in progress. As previously communicated, toll contracts represent around 75% of our US corn sweetener volumes, significantly reducing the volume of our business that is re-contracted in any single year.

EASTSTARCH RE-ALIGNMENT

The process of obtaining regulatory approval for the re-alignment of the Eaststarch joint venture in Europe is now concluded and we expect to complete this transaction during the third quarter of the financial year.

The Group will report the results of the disposed elements of the Eaststarch joint venture within Discontinued Operations in the financial year ending 31 March 2016. In light of this, in its presentation of adjusted performance measures, the Group will cease the use of proportionate consolidation of joint ventures and adopt equity accounting for joint ventures.

We will publish shortly on our website (www.tateandlyle.com) comparative financial information for the six month period to 30 September 2014 and for the year ended 31 March 2015 showing the impact of these changes.

OUTLOOK

Overall, before the impact of exchange rate movements1 and the final timing of the completion of the Eaststarch transaction, expectations for the Group’s full year performance remain unchanged from our guidance issued at our Full Year results in May 2015.

1 Guidance assumed exchange rate of GBP: USD £1.00:$1.54.

END

A conference call will be held today at 8:00am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 3562780

A replay of this call will be available after the end of the live call for 14 days until 21 October 2015.

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151007006229/en/

Copyright Business Wire 2015

Date   Source Headline
8th Dec 20172:39 pmBUSDirector Declaration
4th Dec 20171:40 pmBUSDirector/PDMR Shareholding
24th Nov 201712:54 pmBUSDirector/PDMR Shareholding
20th Nov 20173:21 pmBUSHolding(s) in Company
16th Nov 20171:17 pmBUSHolding(s) in Company
13th Nov 20171:08 pmBUSHolding(s) in Company
2nd Nov 20177:00 amBUSHalf-year Report
1st Nov 20175:00 pmBUSHolding(s) in Company
19th Sep 20174:16 pmBUSHolding(s) in Company
13th Sep 201710:00 amBUSDirector/PDMR Shareholding
1st Sep 201710:00 amBUSTotal Voting Rights
17th Aug 201711:38 amBUSDirector/PDMR Shareholding
9th Aug 20174:00 pmBUSDirectorate change
3rd Aug 201711:00 amBUSResult of the External Audit Tender
27th Jul 20172:37 pmBUSResult of AGM
27th Jul 20177:00 amBUSTrading Statement
3rd Jul 201712:35 pmBUSTotal Voting Rights
3rd Jul 201712:34 pmBUSBlock listing Interim Review
30th Jun 20173:36 pmBUSDirector/PDMR Shareholding
29th Jun 20173:37 pmBUSDirector/PDMR Shareholding
26th Jun 20173:40 pmBUSDirector/PDMR Shareholding
19th Jun 20174:21 pmBUSAnnual Financial Report
16th Jun 20174:20 pmBUSDirector/PDMR Shareholding
14th Jun 20174:31 pmBUSHolding(s) in Company
1st Jun 20173:40 pmBUSTotal Voting Rights
31st May 20173:11 pmBUSHolding(s) in Company
26th May 201711:40 amBUSHolding(s) in Company
25th May 20177:00 amBUSFinal Results
18th May 20172:40 pmBUSHolding(s) in Company
2nd May 201711:55 amBUSTotal Voting Rights
26th Apr 201710:52 amBUSHolding(s) in Company
11th Apr 20175:05 pmBUSDirector/PDMR Shareholding
4th Apr 20173:09 pmBUSDirector/PDMR Shareholding
4th Apr 201710:53 amBUSTotal Voting Rights
1st Mar 20179:58 amBUSTotal Voting Rights
16th Feb 20176:21 pmBUSTransaction in Own Shares
15th Feb 20176:18 pmBUSTransaction in Own Shares
14th Feb 20175:54 pmBUSTransaction in Own Shares
13th Feb 20176:26 pmBUSTransaction in Own Shares
13th Feb 201710:09 amBUSDirector/PDMR Shareholding
9th Feb 20177:00 amBUSTrading Statement
1st Feb 201712:18 pmBUSCompany Secretary Change
1st Feb 201710:00 amBUSTotal Voting Rights
20th Jan 20175:42 pmBUSTransaction in Own Shares
19th Jan 20175:51 pmBUSTransaction in Own Shares
18th Jan 20175:52 pmBUSTransaction in Own Shares
17th Jan 20175:39 pmBUSTransaction in Own Shares
16th Jan 20176:07 pmBUSTransaction in Own Shares
13th Jan 20176:13 pmBUSTransaction in Own Shares
13th Jan 20179:43 amBUSCommencement of Share Purchase Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.